Look behind the lecture: real-world evidence in regulatory decision-making

Written by The Evidence Base

In this feature, Jonathan Andrus (Clinical Ink, PA, USA) discusses his presentation from DIA 2019 (23–27 June, CA, USA) concerning the validity of real-world evidence (RWE) and its use in regulatory decision-making. Please can you introduce yourself and your institution? I am the Chief Business Officer at Clinical Ink (PA, USA). Clinical Ink is dedicated to transforming clinical development — from source to submission — by creating a completely paperless clinical trial platform for sites, sponsors, contract research organizations (CROs) and patients. We provide technology solutions that directly capture eSource data and documents and engage patients for more streamlined clinical development. I...

To view this content, please register now for access

It's completely free